Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors Samples of in vitro cultured T cells and PBMCs obtained ...
Adaptimmune Therapeutics plc has announced that data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results